BeiGene Signs an Exclusive Option and License Agreement with Leap Therapeutics for DKN-01


  • Leap to receive $3M up front, up to $132M development, regulatory, and sales milestones plus royalties on sales of product. BeiGene to get an exclusive option to license DKN-01, for its development and commercialization in Asia (ex-Japan), Australia, New Zealand
  • Post the results of proof-of-concept study BeiGene will exercise the option and will pay additional payments to Leap. Additionally, BeiGene to make $5M equity investment in Leap as part of the contemporaneous $27M equity financing 
  • DKN-01 is a mAb that blocks & binds the activity of Dickkopf-1 (DKK1) protein and will be evaluated in combination with tislelizumab and CT among 40 patients & 20 patients with 2L gastric cancer (GC) /gastroesophageal junction cancer (GEJ) & 1L GC/GEJ respectively, with expected initiation in H1’20

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox